1336-1337 / 2605
Recent studies on SBRT for HCC (3/2011 -)
NCCN version 2 2015: SBRT can be considered as an alternative to ablation and/or
embolization for patients with 1-3 lesions, Child-Pugh A disease and minimal or no extrahepatic
disease or when those therapies have failed or are contraindicated.
6. Sanuki N, Takeda A, Oku Y et al. Hepatol Res 2014.
7. Bujold A, Massey CA, Kim JJ et al. J Clin Oncol 2013; 31: 1631-1639.
8. Jang WI, Kim MS, Bae SH et al. Radiat Oncol 2013; 8: 250.
9. Andolino DL, Johnson CS, Maluccio M et al. Int J Radiat Oncol Biol Phys 2011; 81: e447-453.
10. Kwon JH, Bae SH, Kim JY et al. BMC Cancer 2010; 10: 475.
High local control
Subst ntial toxicity